EP2220071A2 - Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation - Google Patents

Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation

Info

Publication number
EP2220071A2
EP2220071A2 EP08851719A EP08851719A EP2220071A2 EP 2220071 A2 EP2220071 A2 EP 2220071A2 EP 08851719 A EP08851719 A EP 08851719A EP 08851719 A EP08851719 A EP 08851719A EP 2220071 A2 EP2220071 A2 EP 2220071A2
Authority
EP
European Patent Office
Prior art keywords
sunitinib
malate
theta
pxrd pattern
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08851719A
Other languages
German (de)
English (en)
Inventor
Alexandr Jegorov
Pavel Vraspir
Judith Aronhime
Ales Gavenda
Paolo Angioletti
Peter Lindsay MACDONALD
Francesca Scarpitta
Marco Villa
Ettore Bigatti
Augusto Canavesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to EP10166182A priority Critical patent/EP2253629A1/fr
Publication of EP2220071A2 publication Critical patent/EP2220071A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention encompasses Sunitinib hemi-L-malate. In one embodiment, the invention encompasses a crystalline form of sunitinib hemi-
  • Figure 8 illustrates a powder X-ray diffraction pattern of composition I containing Sunitinib base and L-malic acid.
  • Figure 8a illustrates a powder X-ray diffraction pattern of composition I containing
  • Figure lla illustrates a powder X-ray diffraction pattern of composition L containing Sunitinib base and L-malic acid (zoomed).
  • Figure 21 illustrates a DSC thermogram of of sunitinib hemi-L-malate form U.
  • Figure 37 illustrate a powder XRD pattern of crystalline Sunitinib base Form II.
  • Sunitinib base characterized by crystalline Sunitinib base characterized by data selected from a group consisting of a PXRD pattern having any 5 peaks selected from the list consisting of: 3.8, 7.8, 9.0, 10.2, 11.8, 15.8, 17.9, 20.3, 26.1 and 26.8 deg ⁇ 0.2 degrees 2-theta, a PXRD pattern having peaks at about 9.0 and 26.1 ⁇ 0.2 degrees 2-theta and any 3 peaks at positions selected from the group consisting of 3.8, 7.8, 10.2, 11.8, 15.8, 17.9, 20.3 and 26.8 deg ⁇ 0.2 degrees 2-thetaa PXRD pattern as depicted in Figure 37 and combination thereof.
  • the crystalline racemic sunitinib malate Form A can be further characterized by data selected from the group consisting of: a PXRD pattern having peaks at about 5.7, 8.0, 12.5, 14.7 and 18.3 ⁇ 0.2 degrees 2-theta; a PXRD pattern having peaks at about 5.7, 8.0, 9.3, 24.7 and 18.3 ⁇ 0.2 degrees 2-theta; and a PXRD pattern having a single peak at about 27.4 ⁇ 0.2 degrees 2-theta.
  • the crystalline racemic sunitinib malate Form A can be prepared by a process comprising reacting Sunitinib base and racemic malic acid in ethanol to obtain a suspension comprising the said crystalline form.
  • the said solution is maintained at the said temperature for a period of about 15 minutes to about 2 hours. More preferably, the said solution is maintained at the said temperature for a period of about 30 minutes.
  • the present inventions encompasses crystalline sunitinib hemi-L-malate designated form E characterized by a PXRD pattern having peaks at about 6.8 and 11.3 ⁇ 0.2 degrees 2-theta and any 3 peaks at positions selected from the group consisting of: 3.7, 11.9, 15.1, 25.9 and 26.6 ⁇ 0.2 degrees 2-theta.
  • Crystalline sunitinib hemi-L-malate can be further characterized by data selected from the group consisting of: a PXRD pattern having peaks at about 3.7, 6.8, 11.3, 11.9 and 25.9 ⁇ 0.2 degrees 2-theta.
  • the aqueous solution is provided by combining sunitinib base, water and L- malic acid, and heating the combination.
  • the heating is done to a temperature of about 100 0 C.
  • L-malic acid in water to obtain a solution, and lyophilizing the solution; wherein the ratio of L-malic acid to water is about 34:1 w/v, respectively.
  • the invention encompasses a composition containing Sunitinib base and L-malic acid characterized by data selected from a group consisting of a PXRD pattern having any 5 peaks at positions selected from the group consisting of: 6.0, 7.7, 9.2, 12.3, 14.5, 23.0 and 27.3 ⁇ 0.2 degrees 2-theta, a PXRD pattern as depicted in Figure 12, a PXRD pattern as depicted in Figure 12a and combination thereof.
  • This composition can be designated as composition M.
  • composition M can be further characterized by data selected from the group consisting of: a PXRD pattern having peaks at about 6.0, 9.2, 14.5, 23.0 and 27.3 ⁇ 0.2 degrees 2-theta; and a PXRD pattern having peaks at about 7.7, 9.2, 12.3, 14.5 and 23.0 ⁇ 0.2 degrees 2-theta.
  • Composition M can be prepared by a process comprising heating Sunitinib malate to a temperature of about 50°C to 100°C. Preferably, heating is done to a temperature of about 8O 0 C. Preferably, heating is done for a period of about 30 minutes to about 4 hours. More preferably, heating is done for a period of about 2 hours.
  • Composition N can be prepared by a process comprising dissolving sunitinib malate in a mixture of dioxane and water, and lyophilizing the solution. In the lyophilization process, the said solution is subjected to a pressure of less than about one atmosphere, to remove solvent.
  • composition O can be further characterized by a PXRD pattern having four peaks at about 6.0, 7.4, 8.9 and 11.9 ⁇ 0.2 degrees 2-theta.
  • the composition O can be prepared by a process comprising combining sunitinib base, L-malic acid, and a mixture of water, and tetrahydrofuran and evaporating the solvent.
  • the solution is provided by combining sunitinib base, L-malic acid and a mixture of water and dioxane, and heating the said combination to obtain a solution.
  • the invention encompasses a composition containing Sunitinib base and L-malic acid characterized by data selected from a group consisting of a PXRD pattern any 5 peaks at positions selected from the group consisting of: 3.4, 5.6, 9.6, 10.3,
  • the invention encompasses a composition containing Sunitinib base and L-malic acid, characterized by a PXRD pattern having peaks at about 8.5 and 11.3 ⁇ 0.2 degrees 2-theta and any 3 peaks selected from a group consisting of 14.2, 23.2, 24.0 and 26.9 ⁇ 0.2 degrees 2-theta.
  • Example 10 Preparation of composition H containing sunitinib base and L-malic acid. To sunitinib base (form VII, 300 mg) and L-malic acid (101 mg) was added TBME 10 ml) and the slurry was heated 10 min to reflux temperature facilitating formation of the titled composition (368 mg).
  • Example 13 Preparation of composition O containing sunitinib base and L-malic acid.
  • Sunitinib base (form X, dried 70°C, 2 h, 1 mBar, 150 mg)
  • L-malic acid 50 mg in 3 ml of water, 1:1 molar
  • THF 8 ml
  • boiling to dissolution allowed to evaporate at 20°C to dryness in an open baker.
  • Sunitinib base was dissolved in water (250 g) at about 40° by adjusting the pH to 1.5 with IN HCl. The solution was extracted with methyl isobutyl ketone (100 g), the phases were separated and to the aqueous phase dimethylacetamide (20 g) was added. Under strong stirring, the solution was adjusted to pH 8.5 by addition of 25% ammonium hydroxide solution. After one hour the suspension was filtered and the cake was rinsed with 200 g of water. The product was dried at 70° under vacuum overnight to give 12.6 g (56%) of Sunitinib base Form II.
  • Sunitinib Base obtained by reaction of Sunitinib activated carboxylic acid derivative with excess of N,N'-diethylaminoethylamine in tetrahydrofuran, were dissolved with 150g of water and 5Og of HCl IM. The solution was washed with methyl isobutyl ketone at 50°C and then precipitated with ammonia 30% in water to pH 9, the product was filtered and dried in oven under vacuum at 60 0 C for 16 hours.
  • the stirred suspension was cooled at room temperature for 2 hours and filtered; the cake was washed with 5O g of toluene and dried at 50° under vacuum overnight.

Abstract

L'invention concerne l'hémi-L-malate de sunitinib, ses polymorphes, des polymorphes de malate de sunitinib racémique, des compositions contenant une base de sunitinib et de l'acide malique L ou racémique, des procédés pour leur préparation et des compositions pharmaceutiques les contenant.
EP08851719A 2007-11-21 2008-11-21 Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation Withdrawn EP2220071A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10166182A EP2253629A1 (fr) 2007-11-21 2008-11-21 Polymorphes de malate de sunitinib racémique, compositions les contenant et leur préparation

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US98956007P 2007-11-21 2007-11-21
US3016708P 2008-02-20 2008-02-20
US3177308P 2008-02-27 2008-02-27
US4143908P 2008-04-01 2008-04-01
US4213808P 2008-04-03 2008-04-03
US4519608P 2008-04-15 2008-04-15
US4846008P 2008-04-28 2008-04-28
US4846708P 2008-04-28 2008-04-28
US5805308P 2008-06-02 2008-06-02
US5841708P 2008-06-03 2008-06-03
US5922208P 2008-06-05 2008-06-05
US5908808P 2008-06-05 2008-06-05
US6106908P 2008-06-12 2008-06-12
US6192008P 2008-06-16 2008-06-16
US7865008P 2008-07-07 2008-07-07
US8240508P 2008-07-21 2008-07-21
US8415608P 2008-07-28 2008-07-28
US8599108P 2008-08-04 2008-08-04
US8785908P 2008-08-11 2008-08-11
US8855408P 2008-08-13 2008-08-13
US10152708P 2008-09-30 2008-09-30
US10807808P 2008-10-24 2008-10-24
PCT/US2008/084386 WO2009067686A2 (fr) 2007-11-21 2008-11-21 Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10166182.5 Division-Into 2010-06-16

Publications (1)

Publication Number Publication Date
EP2220071A2 true EP2220071A2 (fr) 2010-08-25

Family

ID=40668097

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08851719A Withdrawn EP2220071A2 (fr) 2007-11-21 2008-11-21 Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
EP10166182A Withdrawn EP2253629A1 (fr) 2007-11-21 2008-11-21 Polymorphes de malate de sunitinib racémique, compositions les contenant et leur préparation
EP08852503A Withdrawn EP2220072A2 (fr) 2007-11-21 2008-11-21 Polymorphes de base de sunitinib et procédés pour les préparer

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10166182A Withdrawn EP2253629A1 (fr) 2007-11-21 2008-11-21 Polymorphes de malate de sunitinib racémique, compositions les contenant et leur préparation
EP08852503A Withdrawn EP2220072A2 (fr) 2007-11-21 2008-11-21 Polymorphes de base de sunitinib et procédés pour les préparer

Country Status (4)

Country Link
EP (3) EP2220071A2 (fr)
KR (1) KR20100069705A (fr)
CA (2) CA2699305A1 (fr)
WO (2) WO2009067674A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2274303B1 (fr) * 2008-03-31 2012-08-29 Teva Pharmaceutical Industries Ltd. Procédés de préparation de sunitinib et de sels de ce dernier
CA2720943A1 (fr) 2008-04-16 2009-10-22 Natco Pharma Limited Nouvelles formes polymorphes du sunitinib base
WO2009156837A2 (fr) * 2008-06-26 2009-12-30 Medichem, S.A. Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
EP2297138A1 (fr) * 2008-07-10 2011-03-23 Generics [UK] Limited Procédés de préparation de formes cristallines de malate de sunitinib
EP2342195B1 (fr) 2008-07-24 2014-09-10 Medichem, S.A. Formes cristallines d un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010011834A2 (fr) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib et ses sels et leurs polymorphes
US20120029046A1 (en) * 2008-08-25 2012-02-02 Generics (Uk) Limited Crystalline form of sunitinib and processes for its preparation
AU2009286521A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
EP2181991A1 (fr) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Nouveaux sels de sunitinib
EP2186809A1 (fr) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. Nouvelle forme cristalline du malate de sunitinib
AU2010296849A1 (en) 2009-09-16 2012-05-03 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (fr) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
EP2528913A1 (fr) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Formes cristallines du sel d'acide l-malique du sunitinib
WO2011100325A2 (fr) 2010-02-09 2011-08-18 Sicor Inc. Polymorphes de sels de sunitinib
WO2011107919A1 (fr) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Procédé de préparation directe de sel d'acide malique de sunitinib
AU2011228765A1 (en) 2010-03-18 2012-10-11 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
CN103833733B (zh) * 2012-11-21 2017-08-25 广东东阳光药业有限公司 一种替尼类药物新晶型
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
WO2020216450A1 (fr) 2019-04-25 2020-10-29 Synthon B.V. Composition pharmaceutique comprenant du sunitinib amorphe

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060814A2 (fr) * 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
CA2455050C (fr) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes
CN1308326C (zh) * 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
BRPI0609957A2 (pt) * 2005-05-12 2010-05-11 Pfizer uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
US8389562B2 (en) * 2007-12-12 2013-03-05 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2098521A1 (fr) * 2008-03-06 2009-09-09 Ratiopharm GmbH Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide
CA2720943A1 (fr) * 2008-04-16 2009-10-22 Natco Pharma Limited Nouvelles formes polymorphes du sunitinib base
EP2313396A1 (fr) * 2008-06-23 2011-04-27 Natco Pharma Limited Procédé de préparation de sunitinib de haute pureté et de ses sels pharmaceutiquement acceptables
JP2011526615A (ja) * 2008-07-02 2011-10-13 ジェネリクス・（ユーケー）・リミテッド ３−ピロール置換２−インドリノン誘導体の調製

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009067686A2 *

Also Published As

Publication number Publication date
CA2699305A1 (fr) 2009-05-28
EP2220072A2 (fr) 2010-08-25
KR20100069705A (ko) 2010-06-24
WO2009067674A2 (fr) 2009-05-28
WO2009067686A3 (fr) 2009-11-12
EP2253629A1 (fr) 2010-11-24
WO2009067686A8 (fr) 2009-07-16
CA2699306A1 (fr) 2009-05-28
WO2009067686A2 (fr) 2009-05-28
WO2009067674A3 (fr) 2009-08-27

Similar Documents

Publication Publication Date Title
EP2253629A1 (fr) Polymorphes de malate de sunitinib racémique, compositions les contenant et leur préparation
US8703967B2 (en) Crystal form of sunitinib malate
EP2247585B1 (fr) Formes cristallines du n-[2-(diéthylamino)éthyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidène)méthyl]-2,4-diméthyl-1h-pyrrol-3-carboxamide et procédés pour leur préparation
US20090221595A1 (en) Crystalline form of sitagliptin
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
WO2009053854A2 (fr) Polymorphes de dasatinib et leur procédé de préparation
JP2011512396A (ja) 新規な多形およびその調製方法
US8252805B2 (en) Forms of lapatinib ditosylate and processes for preparation thereof
US7759481B2 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2021236709A1 (fr) Formes à l'état solide de tapinarof
CN102459237B (zh) 6-(1h-咪唑-1-基)-2-苯基喹唑啉的晶型
US20210163498A1 (en) Solid state forms of lorlatinib and their preparation
WO2010027848A2 (fr) Formes de composés de lapatinib et procédés pour leur préparation
US20100256392A1 (en) Polymorphs of sunitinib base and processes for preparation thereof
WO2011100325A2 (fr) Polymorphes de sels de sunitinib
EP3661927A1 (fr) Sels et formes à l'état solide de plinabuline
US20090030207A1 (en) Polymorphs of Dolasetron base and process for preparation thereof
WO2008081475A2 (fr) Nouvelles formes cristallines de zolmitriptan

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100526

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120601